Drugs / [18F]fluoro-2-deoxy-D-glucose (FDG)
[18F]fluoro-2-deoxy-D-glucose (FDG)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02317783 | Jan 2018 → Sep 2019 | breast cancer | University of Utah | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]fluoro-2-deoxy-D-glucose (FDG) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02317783 ↗ |
| Modality | Diagnostic / imaging agent | “Brain scan with imaging tracer used for measuring glucose metabolism in the assessment, diagnosis, and staging of patients with cancer” NCT02317783 ↗ |